文献速递胃肠外科围术期管理与 ERAS

术前抗TNF治疗与溃疡性结肠炎腹部手术术后不良结局的关联

Association of Preoperative Anti-Tumor Necrosis Factor Therapy With Adverse Postoperative Outcomes in Patients Undergoing Abdominal Surgery for Ulcerative Colitis.
PubMed 文献 · JAMA Surg · 2017-08-16

该研究基于美国大型保险索赔数据库,纳入2476例接受腹部手术的溃疡性结肠炎患者,评估术前90天内使用抗TNF药物与术后90天并发症、急诊就诊和再入院的关系。多变量分析显示,仅在回肠储袋肛管吻合术队列中,术前使用抗TNF药物与术后并发症风险升高独立相关(OR 1.38,95%CI 1.05-1.82),而在结肠次全切除或全腹结肠切除及全直肠结肠切除队列中未见显著增加。

要点

  • 术前90天内使用抗TNF药物与回肠储袋肛管吻合术后90天并发症风险升高相关。
  • 在结肠次全切除或全腹结肠切除及全直肠结肠切除患者中,术前抗TNF使用未显著增加并发症。
  • 需在溃疡性结肠炎手术决策中权衡抗TNF使用时机与术式选择。

核心结论

  • 术前90天内使用抗TNF药物在回肠储袋肛管吻合术患者中与更高的90天术后并发症率相关,而在结肠切除或全直肠结肠切除患者中未见显著增加。

研究设计与样本

  • 基于大型全国保险索赔数据库的回顾性队列分析,纳入2005年1月1日至2013年12月31日期间接受首次手术的18岁及以上溃疡性结肠炎患者,共2476例。

主要发现

  • 多变量分析中,回肠储袋队列术前使用抗TNF药物与并发症风险升高独立相关(OR 1.38,95%CI 1.05-1.82)。
  • 结肠切除队列和全直肠结肠切除队列中未观察到术前抗TNF使用与并发症的显著关联。

关键数值与推荐

  • 术前90天内使用抗TNF药物通过医疗保健通用程序编码系统代码识别。
  • 纳入标准要求患者有溃疡性结肠炎ICD-9-CM诊断代码,且排除克罗恩病诊断及未连续参保至少180天者。
  • 主要结局为术后90天并发症、急诊就诊和再入院。

临床怎么用

  • 对于计划行回肠储袋肛管吻合术的溃疡性结肠炎患者,应关注术前90天内抗TNF药物使用可能增加术后并发症的风险。
  • 在结肠次全切除或全腹结肠切除及全直肠结肠切除患者中,术前抗TNF使用未显示显著增加并发症,但需个体化评估。

局限性

  • 研究为回顾性索赔数据分析,可能存在编码错误和未测量混杂因素。
  • 仅纳入参保人群,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite the increasing use of anti-tumor necrosis factor (TNF) therapy in ulcerative colitis, its effects on postoperative outcomes remain unclear, with many patients requiring surgical intervention despite optimal medical management. OBJECTIVE: To assess the association of preoperative use of anti-TNF agents with adverse postoperative outcomes. DESIGN, SETTING, AND PARTICIPANTS: This analysis used insurance claims data from a large national database to identify patients 18 years or older with ulcerative colitis. These insured patients had inpatient and/or outpatient claims between January 1, 2005, and December 31, 2013, with Current Procedural Terminology codes for a subtotal colectomy or total abdominal colectomy, a total proctocolectomy with end ileostomy, or a combined total proctocolectomy and ileal pouch-anal anastomosis. Only data regarding the first or index surgical admission within the time frame were abstracted. Use of anti-TNF agents, corticosteroids, and immunomodulators within 90 days of surgery was identified using Healthcare Common Procedure Coding System codes. Inclusion in the study required the patient to have an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code for ulcerative colitis. Exclusion occurred if the patient had a secondary ICD-9-CM diagnosis code for Crohn disease or if the patient was not continuously enrolled in an insurance plan for at least 180 days before and after the index surgery. Data were collected and analyzed from February 1, 2015, to June 2, 2016. MAIN OUTCOMES AND MEASURES: Outcomes included 90-day complications, emergency department visits, and readmissions. Multivariable logistic regression was used to model covariates, including anti-TNF agent use, on the occurrence of outcomes. RESULTS: Of the 2476 patients identified, 1379 (55.7%) were men, and the mean (SD) age was 42.1 (12.9) years. Among these, 950 (38.4%) underwent subtotal colectomy or total abdominal colectomy, 354 (14.3%) underwent total proctocolectomy with end ileostomy, and 1172 (47.3%) received ileal pouch-anal anastomoses. In univariate analyses, increased postoperative complications were observed among patients in the ileal pouch cohort who received anti-TNF agents preoperatively vs those who did not (137 [45.2%] vs 327 [37.6%]; P = .02) but not among those in the colectomy or proctocolectomy cohorts. An increase in complications was also observed on multivariable analyses among patients in the ileal pouch cohort (odds ratio, 1.38; 95% CI, 1.05-1.82). CONCLUSIONS AND RELEVANCE: Unlike preoperative anti-TNF agent use among patients who underwent colectomy or total proctocolectomy and experienced no significant increase in postoperative complications, anti-TNF agent use within 90 days of surgery among patients who underwent ileal pouch-anal anastomosis was associated with higher 90-day postoperative complication rates.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Kulaylat AS, Kulaylat AN, Schaefer EW, et al. Association of Preoperative Anti-Tumor Necrosis Factor Therapy With Adverse Postoperative Outcomes in Patients Undergoing Abdominal Surgery for Ulcerative Colitis. JAMA Surg. 2017. PMID: 28614561. doi:10.1001/jamasurg.2017.1538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。